van der Vaart Sandra D
Known title: EVP, Chief Legal OfficerCIK: 0001537208
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Barclays Upgrades Fortrea, Boosts Target to $23. Barclays has upgraded Fortrea Holdings to overweight and lifted its target price to $23. The upgrade follows a recent rise in the stock price and a mention of the company as an overrated pick in a Yahoo article. Analysts still see upside potential, with the average target of $21.04 and a 52‑week range that includes the new level. The stock’s high‑beta rating indicates it may continue to move sharply with market swings.
Transaction History
| LH | ▲ Buy | Grant | 6,382 | $0 | 3/26/2026 | View on chart |
| LH | ▼ Sell | Tax Withholding | 2,722 | $731K | 3/26/2026 | View on chart |
| LH | ▼ Sell | Open Market | 548 | $156K | 2/27/2026 | View on chart |
| LH | ▲ Buy | Option Exercise | 376 | — | 2/11/2026 | View on chart |
| LH | ▼ Sell | Tax Withholding | 99 | $29K | 2/11/2026 | View on chart |
| LH | ▼ Sell | Tax Withholding | 93 | $25K | 2/9/2026 | View on chart |
| LH | ▲ Buy | Option Exercise | 353 | — | 2/7/2026 | View on chart |
| LH | ▼ Sell | Tax Withholding | 101 | $28K | 2/6/2026 | View on chart |
| LH | ▲ Buy | Option Exercise | 387 | — | 2/6/2026 | View on chart |
| LH | ▲ Buy | Option Exercise | 3,903 | $513K | 8/13/2025 | View on chart |
| LH | ▼ Sell | Open Market | 3,903 | $1.1M | 8/13/2025 | View on chart |
| LH | ▼ Sell | Open Market | 1,900 | $453K | 5/1/2025 | View on chart |
| LH | ▲ Buy | Grant | 3,325 | $0 | 3/27/2025 | View on chart |
| LH | ▼ Sell | Tax Withholding | 1,352 | $313K | 3/27/2025 | View on chart |
| LH | ▼ Sell | Open Market | 1,314 | $330K | 2/25/2025 | View on chart |
| LH | ▲ Buy | Option Exercise | 323 | — | 2/11/2025 | View on chart |
| LH | ▼ Sell | Tax Withholding | 86 | $21K | 2/11/2025 | View on chart |
| LH | ▲ Buy | Option Exercise | 354 | — | 2/7/2025 | View on chart |
| LH | ▼ Sell | Tax Withholding | 94 | $23K | 2/7/2025 | View on chart |
| LH | ▼ Sell | Tax Withholding | 102 | $25K | 2/6/2025 | View on chart |
| LH | ▲ Buy | Option Exercise | 386 | — | 2/6/2025 | View on chart |
| LH | ▼ Sell | Open Market | 1,000 | $239K | 11/21/2024 | View on chart |
| LH | ▼ Sell | Open Market | 2,000 | $454K | 8/19/2024 | View on chart |
| LH | ▼ Sell | Open Market | 1,800 | $379K | 5/14/2024 | View on chart |
| LH | ▼ Sell | Open Market | 200 | $42K | 5/14/2024 | View on chart |
| LH | ▼ Sell | Open Market | 3,553 | $770K | 3/28/2024 | View on chart |
| LH | ▼ Sell | Tax Withholding | 2,605 | $564K | 3/27/2024 | View on chart |
| LH | ▲ Buy | Option Exercise | 6,158 | — | 3/27/2024 | View on chart |
| LH | ▼ Sell | Open Market | 237 | $54K | 2/13/2024 | View on chart |
| LH | ▼ Sell | Tax Withholding | 87 | $20K | 2/12/2024 | View on chart |
| LH | ▲ Buy | Option Exercise | 324 | — | 2/11/2024 | View on chart |
| LH | ▼ Sell | Open Market | 259 | $58K | 2/8/2024 | View on chart |
| LH | ▼ Sell | Tax Withholding | 94 | $21K | 2/7/2024 | View on chart |
| LH | ▲ Buy | Option Exercise | 353 | — | 2/7/2024 | View on chart |
| LH | ▼ Sell | Open Market | 193 | $43K | 2/5/2024 | View on chart |
| LH | ▲ Buy | Option Exercise | 264 | — | 2/2/2024 | View on chart |
| LH | ▼ Sell | Tax Withholding | 71 | $16K | 2/2/2024 | View on chart |
| LH | ▼ Sell | Open Market | 212 | $51K | 6/29/2023 | View on chart |
| FTRE | ▼ Sell | Other | 7,816 | $0 | 6/20/2023 | View on chart |
| LH | ▼ Sell | Tax Withholding | 1,371 | $308K | 3/30/2023 | View on chart |
| LH | ▲ Buy | Grant | 3,609 | $0 | 3/30/2023 | View on chart |
| LH | ▼ Sell | Tax Withholding | 78 | $19K | 2/13/2023 | View on chart |
| LH | ▲ Buy | Option Exercise | 290 | — | 2/11/2023 | View on chart |
| LH | ▼ Sell | Open Market | 219 | $53K | 2/7/2023 | View on chart |
| LH | ▼ Sell | Tax Withholding | 81 | $20K | 2/6/2023 | View on chart |
| LH | ▲ Buy | Option Exercise | 300 | — | 2/4/2023 | View on chart |
| LH | ▼ Sell | Open Market | 173 | $44K | 2/3/2023 | View on chart |
| LH | ▼ Sell | Tax Withholding | 64 | $16K | 2/2/2023 | View on chart |
| LH | ▲ Buy | Option Exercise | 237 | — | 2/2/2023 | View on chart |
| LH | ▼ Sell | Open Market | 2,449 | $679K | 3/29/2022 | View on chart |
| LH | ▼ Sell | Tax Withholding | 1,792 | $495K | 3/28/2022 | View on chart |
| LH | ▲ Buy | Grant | 4,241 | $0 | 3/27/2022 | View on chart |
| LH | ▼ Sell | Open Market | 207 | $57K | 2/15/2022 | View on chart |
| LH | ▼ Sell | Tax Withholding | 77 | $21K | 2/14/2022 | View on chart |
| LH | ▲ Buy | Option Exercise | 284 | — | 2/12/2022 | View on chart |
| LH | ▼ Sell | Open Market | 218 | $60K | 2/7/2022 | View on chart |
| LH | ▼ Sell | Tax Withholding | 82 | $23K | 2/4/2022 | View on chart |
| LH | ▲ Buy | Option Exercise | 300 | — | 2/4/2022 | View on chart |
| LH | ▼ Sell | Open Market | 172 | $47K | 2/3/2022 | View on chart |
| LH | ▲ Buy | Option Exercise | 236 | — | 2/2/2022 | View on chart |
| LH | ▼ Sell | Tax Withholding | 64 | $17K | 2/2/2022 | View on chart |
| LH | ▼ Sell | Open Market | 4,500 | $1.3M | 9/15/2021 | View on chart |
| LH | ▲ Buy | Option Exercise | 4,500 | $382K | 9/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Labcorp to Acquire OPKO Health's BioReference Assets for $722M
Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.
Labcorp to Acquire OPKO Health's BioReference Assets for $722M. Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.